CLEVELAND, July 11, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced that the company's MRIdian® Linac has been selected for installation at Centre Georges-François Leclerc (CGFL) in Dijon, France as part of a tender award contract with UNICANCER, a hospital network of 19 French Comprehensive Cancer Centers (FCCCs).

MRIdian Linac combines the latest innovations in precision radiation delivery with ground-breaking MR image guidance. It enables daily real-time on-table adaptive radiotherapy (ROAR™) treatment, allowing clinicians to quickly and dynamically adjust for anatomical changes that may naturally occur each day throughout the patient's course of treatment. The technology also allows oncologists to visualize and actively track the unique contours of the tumor and surrounding organs during radiation delivery using a non-ionizing, streaming video perspective. Combined, these capabilities provide the clinicians with the tools to potentially improve tumor targeting precision and thus allow for delivery of higher, and potentially more effective, radiation doses.

UNICANCER is the only French hospital federation exclusively dedicated to oncology and the leading academic promoter of oncology clinical trials in Europe. Its FCCCs are private, non-profit hospitals that guarantee the same quality of care across institutions and allow for quick and secure access to innovations in the areas of care and research.

"We carefully evaluated the options for MR-guided radiation therapy in Europe and selected MRIdian Linac for its combination of high-fidelity beam delivery and ability to deliver advanced SBRT," said Professor Charles Coutant, General Manager of CGFL.

"MRIdian Linac's ability to deliver adaptive radiotherapy helps us overcome challenges like real-time anatomical movement and day-to-day changes in the shape, size or location of the tumor, which should allow for better targeting accuracy and sparing of nearby organs and healthy tissue," said Karine Peignaux, M.D., Head of Radiation Therapy at CGFL.

"By integrating MRI with a Linac, ViewRay has foreseen the future of external radiotherapy, which is linked to improvements in target and organ definition based on the anatomy of the day using MRI," said Professor Gilles Créhange, Head of Clinical R&D, Radiation Therapy at CGFL. "Targeting cancer and delivering radiation under real-time MRI guidance should improve treatment with the potential for lower rates of toxicity."

About ViewRay®

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include the advancement of science, and the ability of MRI-guided radiation therapy programs to enable more treatment options, improved tumor targeting precision and higher, more effective, radiation dose. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.